Talphera, Inc. announced as part of its commitment to operating with best practices in corporate governance, its Board of Directors has decided to reduce the size of the Board from ten to seven directors. Three directors, Howard Rosen, Richard Afable and Pamela Palmer have voluntarily agreed to resign from the Board of Directors, effective immediately. Dr. Palmer will continue in her current role of Chief Medical Officer and member of the executive leadership team, with a focus on successfully completing the Niyad? registrational study later this year.

On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc., and any and all committees thereof, effective immediately. At the time of their resignations, Dr. Afable served on the Compensation Committee and Mr. Rosen served on the Audit Committee. Dr. Afable and Mr. Rosen?s resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

On February 28, 2024, Pamela P. Palmer, M.D., Ph.D. resigned as a member of the Company?s board of directors effective immediately. Dr. Palmer will remain as the Company?s Chief Medical Officer. Dr. Palmer?s resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

Following the above resignations, the board of directors reconstituted the committees of the board of directors as follows: Audit Committee: Jill Broadfoot (Chair); Marina Bozilenko and Stephen J. Hoffman, M.D., Ph.D. Compensation Committee: Mark Wan (Chair); Stephen J. Hoffman, M.D., Ph.D. and Abhinav Jain. Financing and Strategic Transactions Committee: Marina Bozilenko (Chair); Adrian Adams; Abhinav Jain and Mark Wan. Nominating and Corporate Governance Committee: Adrian Adams (Chair); Abhinav Jain and Mark Wan.